ASCO 2022 Conference Coverage
ASCO 2022 on B-PRISM: A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in High-Risk SMM
By
ASCO 2022 Conference Coverage
FEATURING
Omar Nadeem
By
ASCO 2022 Conference Coverage
FEATURING
Omar Nadeem
Login to view comments.
Click here to Login
